Long-term follow-up after a vision gene eye injection
Part of Eyes & vision, Genetic & congenital clinical trials.
This study checks how people who previously received a gene therapy eye injection (vMCO-I) are doing over the long term. It may help researchers understand long-lasting effects and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received vMCO-I in an earlier (parent) study
- That earlier vMCO-I treatment must have been given as an eye injection
- You must be willing and able to give consent for this follow-up study
- If you do not agree to participate, you cannot join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
This trial checks whether a stem cell treatment is safe over the long term for people with retinitis pigmentosa. You would get an injection near the eye and then do several follow-up eye tests and quality-of-life surveys to monitor effects.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
This trial tests whether stem cell–based injections near the eye can slow vision loss in people with retinitis pigmentosa. It compares stem cells made from umbilical cord tissue and asks participants to complete several eye tests over time to measure vision changes.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.